CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 103 enrolled
Drug / intervention
Simvastatin +1 moredrug
Likely dose
Simvastatin 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00486044
NCT00486044Phase 2Completed
CompareCT.gov

Effect of Statins on Pathobiology of Alzheimer's Disease

University of Wisconsin, Madison·interventional·Posted Jun 13, 2007·Updated Mar 5, 2019

In Brief

A Phase 2 clinical trial evaluating Simvastatin and Placebo for Alzheimer Disease. Completed, enrolled 103 participants across 1 site.

Detailed Summary

The purpose of this study is to see how simvastatin, a cholesterol-lowering drug, affects processes related to the development of Alzheimer's disease, including: 1) levels of a substance called beta-amyloid-42 found in the spinal fluid surrounding the brain, 2) blood flow in the brain, 3) inflammation in the brain, and 4) cognitive function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA), Paul Beeson Faculty Scholars Program, The John A. Hartford Foundation, The Atlantic Philanthropies, Starr Foundation, American Federation for Aging Research, Merck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 13, 2007
Enrollment StartFeb 1, 2005
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 19.1 years ago

Interventions

Simvastatindrug

40 mg tablet each night for one month, then 80 mg for 8 months

Placebodrug

Matching tablet each night for 9 months